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In this proposal, we set out to a) systematically monitor splicing variant profiles in breast cancer susceptibility genes and b) explore the role of alternative splicing in breast chemotherapy using a global strategy. In doing so, we hope to identify and validate candidate splicing variants involved in tumorigenesis using polony digital exon-profiling and functional assays. We are moving forward on four fronts -1) the barcode methodology is in development; 2) we are working with state-of-the art capture arrays; 3) we are using the very latest RNA sequencing technology and 4) we are conducting comprehensive analyses of existing splice site variants in known breast cancer susceptibility genes. In part 3, we have generated over 5 million reads that have been aligned to the splice junction libraries, and we are using these reads to quantify and characterize alternative splicing events. Moreover, we will add value to this project by attempting to identify fusion proteins. In part 4, we have determined that the BRCA2 isoform known as BRCA2Δex12 is not associated with a recognizable phenotype. This work is now in press in Human Mutation.
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Introduction
In this proposal, we aimed to a) systematically monitor splicing variant profiles in breast cancer susceptibility genes and b) explore the role of alternative splicing in breast chemotherapy using a global strategy. In doing so, we hoped to identify and validate candidate splicing variants involved in tumorigenesis using polony digital exon-profiling and functional assays. This annual report summarizes our progress in the first year of this two-year award.
Body

Verbatim -from S.O.W
Objective 1: To profile splicing patterns of 100 breast cancer-related genes in 30 normal and tumor breast cell lines
Objective 2: To profile splicing patterns of 100 cancer-related genes in lymphocytes and breast tissues
Objective 3: Data analysis and validation to determine the role of aberrant splicing in breast tumourgenesis (months [8] [9] [10] [11] [12] These objectives can be summarized in terms of the expected Results/Deliverables from Year 1: 1) Optimizing the method of bar-code PCR-sequencing for studying alternative splicing at candidate loci. 2) Identifying splicing variants associated with increased breast cancer susceptibility derived from the candidate loci. Year 2 focuses more on drug sensitivity, and how splicing patterns may determine the response to certain chemotherapeutic agents.
1) Optimizing the method of bar-code PCR-sequencing for studying alternative splicing at candidate loci
As the key subject of this synergistic IDEA award was the development of a molecular barcode, as a prelude to large scale analysis of splicing patterns present in the breast cancer genome, we undertook a the first step to evaluate the "Molecule Barcode" technology to monitor alternative splicing in tumor samples, we have performed a series of proof-of-concept experiment. The results showed that the effective sequencing length can be virtually extended from 36 bp to 300-400 bp. While the results are encouraging, we observed that the coverage is biased towards the middle of reconstructed molecules. In parallel with attempts to improve our technology, and to better monitor splicing variants in tumor samples, we switched to an emerging alternative strategy, NimbleGen Sequence-Capture array that can selectively enrich genes of interest (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) for deep sequencing analysis. The captured fragments were then subjected to 454
pyrosequencing to obtain a longer read length (~400bp), which enables better identification of alternative splicing and mutation detection.
We had worked with NimbleGen to design a custom capture array for detail characterizing a larger set breast cancer related genes. The original design was based on 385K array (Nov, 2008) and training date was set for early 2009. Both Ting Ni (post-doctoral fellow, funded by this award, based at Duke University) and Lili Li (PhD candidate, funded from this award, based at McGill University) took the training courses using supplied 385K capture array by NimbleGen during April 7 -9, 2009. Average 288-345 fold of enrichment using supplied genomic DNA suggested the success of training. We then use the real samples of the breast cancer cell line BT20 and drug-resistant BT20 cell lines to practice by ourselves. Real-time PCR results suggested substantial enrichment of desired regions (average enrichment of 267 fold).
During our interactions with NimbleGen, the 2.1M capture array capture array became commercially available with an early release in Feb, 2009. We were offered by NimbleGen to have a free upgrade from 385K array to the most advanced 2.1M array. Given that the new custom array has approximately 6-fold higher capacity, we decided to broaden our research using the high-density array. The new custom array was design in early March, which before the actual training was taken place. After the training, we requested the 2.1M custom array to be delivered. However, there was a logistic mistake from Nimblegen and our order remained showing as 385K array in their ordering system. The issue had been resolved in June, 2009. The array order is currently in production department and we expect to have the array delivered within next 2-4 weeks.
While waiting for the custom array to be delivered, we have constructed two libraries with BT20 cell line and its derivative that resistant to dastanib, an important new tyrosine kinase drug that has considerable activity in leukemia and in some solid tumors, including breast cancer. We have worked out an improved RNA-Seq protocol to keep the strand information during library construction. Therefore, the library will allow us not only to detect splicing variants but also antisense transcripts in cell transcriptome. We have obtained initial information that antisense transcripts are broad phenomena of eukaryotic transcriptomes and may play essential roles in mammalian gene regulation. The innovative strategy we developed, in fact, can reliably capture this hidden layer of mammalian transcriptomes and is expected to provide novel insights into altered gene expression in addition to alternative splicing.
Lastly, it is worth pointing out the NimbleGen capture array is directly coupled with 454 pyrosequencing platform. To prepare further study with large number of samples, we also tested the strategy to convert the captured sequences to library amenable for Illumina/Solexa Sequencing (which is approximately 10 times more cost-effective than 454 pyrosequencing). This led to a optimized protocol by which the 454 library can be adapted for Solexa sequencing through a circularization step.
In addition to the analysis of the BT20 lines, In addition, through collaboration with the Breakthrough Breast Cancer Institute in the UK, we have collected RNA samples from 34 breast tumor lines that represent 5 different types of breast cancers classified by expression profiles: luminal epithelial-like subtypes A and B, basal epithelial-like, ERBB2-amplification associated and normal breast-like subtypes. The fact that the response profiles of these lines to Dasatinib have been published, will allow us to assess whether or not the genetic alterations identified in a induced resistance model can be applied to intrinsic resistance. Thus, as soon as our pipeline is well-developed we will be able to test and validate candidate genes using this wellcharacterised set of breast cancer cell lines.
A third strategy we have used is to sequence the RNA of a breast cancer cell line directly. Because the pace of technological innovation is substantially faster than the granting process, our original proposal to analyze the splicing patterns of 100 candidate breast cancer genes (using the barcode and/or capture array strategy) has been augmented this approach with state-of-the art whole transcriptome sequencing. In other words, in this part of the project, we aim to analyze not the 100 "top" candidate breast cancer susceptibility genes, but instead all ~24,000 genes. This project has been led by PI Foulkes and co-I Majewski. To date, we have used Illumina/Solexa RNA sequencing to generate over 40 million, 50 bp reads from the transcriptome of the well known breast cancer cell line, HCC1937. The reads were mapped to the transcriptome using ELAND and CASSAVA software, and visualized using the Illumina Genome Studio. Summary of the mapping is presented in Table 1 below. Over 5 million reads are aligned to the splice junction libraries, and we are using these reads to quantify and characterize alternative splicing events. However, one of our main interests is to identify novel splice isoforms (not present in most reference splice libraries). To this end, we are pursuing three approaches: 1) Mapping sequencing reads to exhaustive splice junction libraries representing all possible splice junctions within each gene; 2) monitoring excess reads that map to normally intronic sequences -this is meant to detect novel intron retention events; 3) creating a library and heuristic algorithms for mapping reads to an exhaustive library joining all exons across all of the genes in the human genome -this last approach will allow us to detect all known and novel alternative splicing events, trans-splicing (across genes), as well gene fusion events that are known to occur in many tumors. We discuss this last, most inclusive approach below.
Gene fusions are the result of chromosomal alterations involving two genes. These chimeras may have severe phenotypic effects, such as the well-studied BCR-ABL1 fusion protein implicated in chronic myelogenous leukemia (Shtivelman et al., 1985) and TMPRSS2-ERG found in many cases of prostate cancer (Tomlins et al., 2005) . New efforts using high-throughput sequencing have resulted in new discoveries of gene fusions. This has prompted interest in determining whether these chromosomal aberrations may be specific to cancer and if they are, may theoretically serve as an ideal diagnostic and therapeutic target (Prensner and Chinnaiyan, 2009 ).
To detect gene fusions using our RNA sequencing data, we followed a similar approach described by Maher et al. (2009) . Of a total of 40 million 50 bp reads sequenced from the HCC1937 cell line, approximately 1.5 million reads were determined to be non-mapping after analyzing the data through the Illumina pipeline (version 1.3). Non-mapping reads are those which did not have a unique alignment to the reference genome. We limited our gene fusion analysis to only these reads as they may potentially characterize breakpoints of gene fusions not found in the reference genome.
Firstly, we downloaded from the UCSC Genome Database (hg18 assembly) the set of exon genomic sequences from all mature mRNA RefSeq transcripts. As the mRNA of gene fusions would typically involve the fusion of exon sequences from two different genes, we retained only the boundary sequences of each exon (i.e. 49 bp sequence from the left boundary of an exon and 49 bp sequence from the right boundary of an exon), in order to identify reads that may span such exon-exon boundaries. Blat (Kent, 2002 ) was used to align the non-mapping reads against this list of exon boundary sequences. Using a set of in-house scripts written in Python, we filtered the results for alignments such that a read was partially aligning to an exon boundary. Of these partial alignments, we further identified whether its remaining unaligned sequence aligned to another exon region either from the Blat analysis or by simple string matching techniques. In addition to gene fusion detection, our approach will lead to the detection of novel splicing events and transcript isoforms. It will be possible to observe previously uncharacterized exon-exon junctions from a particular gene, which may represent a transcript isoform. Using our system, we will be able to test splice variants that you discover".) He showed that both p.I2285V and an allele completely lacking exon 12 (BRCA2Δex12) were functionally indistinguishable from wild-type BRCA2. This was based on their sensitivity to DNA-damaging agents, effect on irradiation-induced Rad51 foci formation, homologous recombination and overall genomic integrity. Taken together, our clinical and functional studies strongly suggested that exon 12 is functionally redundant and therefore missense variants in this exon are likely to be neutral. We believe that such comprehensive functional studies will be important adjuncts to genetic studies of variants.
Thus, although the original the molecular barcode strategy has not yet been perfected, we are moving forward on four fronts -as stated, 1) the barcode methodology is in development; 2) we are working with state-of-the art capture arrays; 3) we are using the very latest RNA sequencing technology and 4) We are conducting comprehensive analyses of existing splice site variants in known breast cancer susceptibility genes. As stated above, in part 3, we have generated over 5 million reads that have been aligned to the splice junction libraries, and we are using these reads to quantify and characterize alternative splicing events. Moreover, we will add value to this project by attempting to identify fusion proteins, as discussed above. In part 4, we have determined that the BRCA2 isoform known as BRCA2Δex12 is not associated with a recognizable phenotype.
Key Research Accomplishments
• Publication in press from the Foulkes group 
Conclusion
In this proposal, we have set out to evaluate the importance of splicing for breast cancer biology. We are employing a number of state-of-the-art technologies -in particular, we are developing the very novel "Molecule Barcode" technology. As this has been a little slower than we would have liked, in addition we have followed two other avenues -a custom-made capture array to study splicing events in breast cancer and RNA sequencing, which is a relatively unbiased approach to the problem. Finally, we have carefully evaluated the significance of one particular isoform of BRCA2, and have shown that it is not associated with an increased risk for breast cancer. This is important for the families whose members carry this variant. In the future, we will continue to focus on developing our innovative technology development but will also pursue alternative strategies, as described above. If necessary, we will also continue to collaborate with Dr. Shyam Sharan in attempting to classify splicing variants in the important breast cancer susceptibility genes, BRCA1 and BRCA2. The knowledge gained from this project thus far could directly benefited women with breast cancer and those at risk of breast cancer. We hope that our approach will lead to significant insights into the more general question of the importance of alternative splicing in breast cancer biology. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Splice site mutations are a common cause of exclusion of an exon and many have been identified in BRCA1 and BRCA2 (Frank et al., 2002) . More recently, variants that do not alter the consensus splice site sequences but affect splicing have been identified (Liu et al., 2001 ). These mutations result in the interruption of exon splicing regulators and have been increasingly recognized as important causes of exon exclusion or intron inclusion . Since the BRCA2: p.I2285V was reported to be associated with increased exclusion of exon 12 in one family, we were interested to establish if this were the case in other individuals carrying this variant, and whether disruption of an ESE was a likely mechanism. Moreover, we wondered if exclusion of exon 12 was associated with an identifiable phenotype. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   5 potential effect of a variant on splicing, however, is not measured in these analyses. Taking all the observations together, it seems possible that this variant affects splicing and thus has a subtle effect on risk, perhaps akin to the risk associated with so-called low penetrance breast cancer genes identified recently (Pharoah et al., 2008) . Here, we describe investigation of the relationship between this variant and exclusion of exon 12; b) the functional consequences of exclusion of exon 12 of BRCA2 and c) the potential effect of this variant on breast cancer risk.
Materials and Methods
BRCA2: p.I2285V pedigrees
We collected information from four families where at least one individual carried the BRCA2: p.I2285V variant. These pedigrees are shown in supplementary figures 1a-d.
Lymphocyte RNA and DNA was extracted from one carrier of the variant from each family and were used in the experiments described below. All participants signed an informed consent form. The details of each family are described in the figure legend accompanying supplementary figure 1.
Testing for inclusion or exclusion of exon 12 in humans
We confirmed the co-occurrence of c.6853A>G / p.I2285V (BIC name: 7081A>G) with another deleterious BRCA2 mutation c.5946delT / p.S982RfsX20 (BIC name: 6174delT), using a blood sample from a patient carrying both alleles (see supplementary figure 2 and accompanying legend). We used RNA extracted from blood samples from this proband and three others (supplementary figure 1) using PAXgene (Qiagen) kit and cDNA was 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Amplification products were separated in a 1.6% agarose gel.
Allelic association study
As controls, the study enrolled 475 healthy women collected through the New York Cancer Project (NYCP). The NYCP is a cohort study involving consent for biospecimen collection and follow-up of 8,000 healthy volunteers in the same geographical region as the cases 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 8 used in this study (Mitchell et al., 2004) . For the cases, we genotyped 722 consecutive breast cancer cases unselected for family history or BRCA1/2 status seen at Memorial Sloan-Kettering Cancer Center and collected for the study under IRB approved protocols.
All individuals in the study were self identified as Ashkenazi Jewish. For genotyping of BRCA2 I2285V we used TaqMan allelic discrimination assay under standard manufacture's protocol (Applied Biosystems). The alleles were called using SDS 2.1 software (Applied Biosystems). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 unable to study other family members, we could not establish phase genetically. Instead, by using RNA from this cell line, we showed that exon 12 inclusion and exclusion transcripts were produced from both alleles, but the degree of exclusion was much greater with for the I2285V-associated allele than for the c.6174delT-associated allele. We were able to demonstrate that these variants occur in trans (supplementary Figure 2) . This supports the previous segregation and family history data showing that p.I2285V is very unlikely to be a highly penetrant allele (as discussed above). Nevertheless, we were left with the question of the splicing out of exon 12 -is it frequently associated with BRCA2:p.I2285V, and if so, what is the consequence of this?
Results
Conservation and co-occurrence
Effect of I2285V on the BRCA2 mRNA
The clinical protein truncation test (PTT) of BRCA2 on one individual carrying this variant indicated that exon 12 skipping occurs to a greater degree in this individual than the level in the control samples (data not shown). We searched for splicing regulatory elements located in exon 12 by using the following on-line prediction tools: ESEFinder: http://rulai.cshl.edu/tools/ESE; RESCUE-ESE: http://genes.mit.edu/burgelab/rescue-ese/ ESRsearch:http://ast.bioinfo.tau.ac.il/ESR.htm and PESX: http://cubweb.biology.columbia.edu/pesx/. Using RESCUE-ESE, we identified putative ESEs at the region where the BRCA2: c.6853A>G variant is located. Notably, the variant "G" allele disrupts three of overlapping putative ESEs ( Figure 1A) . By studying exon 12 retention in 4 individuals who carry the p.I2285V variant and two controls, we were able to show quantitatively that this variant significantly increases the exclusion of exon 12 of BRCA2 ( Figure 1B) . The test we used here was to see if the variant was retained 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 in exon 12 by capillary sequencing of exon 12 inclusion transcripts, as a variant promoting exon 12 skipping would result in a diminished signal of itself in the retained exon 12. As shown in Figure 1B, among 3 heterozygotes (I2285V-a, I2285V-b and I2285V-c) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 11 tolerated range. Our next goal was to establish if this splicing out of exon 12 has any functional consequences.
Functional test of c.6853A>G variant and complete deletion of exon 12
To test the functional significance of deletion of exon 12, mouse ES cell based functional assay was used. The BRCA2∆E12 variant was generated in the BAC DNA coding for human BRCA2 and introduced into mouse ES cells containing a single functional copy of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 12 compared the results for the BRCA2∆E12 variant with those obtained for clones that expressed p.I2285V and wild-type BRCA2.
Two clones were then tested extensively for sensitivity to DNA-damaging agents and we found no significant difference for either the BRCA2∆E12 allele or the p.I2285V allele compared to the control cells for any of the six agents used (Figure 3, panels A-F) . As (abbreviated here as Rosa26) locus. We observed similar targeting efficiency in the ES cells expressing BRCA2∆E12, p.I2285V or wild-type BRCA2 ( Figure 5A ). The karyotyping of these cells also did not reveal any significant increase of chromosomal abnormalities due to deletion of exon12 ( Figure 5B and C) . Based on these results we conclude that the deletion of exon12 of BRCA2 does not significantly affect any of its known functions. We have previously demonstrated the utility of the ES cell based assay to detect subtle functional defects in variants that are predicted to be of low risk (Kuznetsov et al., 2008) . However, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 13 the possibility of clinically relevant effects of this allele on breast cancer risk that were not due to the known functions of BRCA2 that we assayed here still remained, so we probed the function of p.12285V from a clinical perspective.
Allelic association study
The loss of exon 12 could have an effect on breast cancer risk that might be insufficiently large to be evident from pedigree analysis, but might still be clinically relevant. To address this question, we assessed the frequency of BRCA2: c.6853A>G in on-going series of Ashkenazi Jewish breast cancer cases and ethnically matched controls (total n = 1197). We identified 10 carriers in 475 controls, and 15 carriers in 722 cases, resulting in an odds ratio for the association between this allele and breast cancer of 0.99, 95% confidence interval 0.44-2.21, P = 0.97. When we adjusted for age, the odds ratio became 0.97 (95% CI: 0.41-2.12), P = 0.88. Setting the alpha at 5%, a study of this size has an 80% power to rule out an allele frequency of 0.053 or greater in the cases, when the allele frequency in controls is 0.021.
Discussion
Here, we describe the analysis of BRCA2: c.6853A>G (BIC nomenclature, 7081A>G, p.12285V), a previously reported VUS. We first confirmed that BRCA2: c.6853A>G cooccurs in trans with other deleterious alleles in BRCA2. We also showed that this variant promotes increased exclusion of exon 12 of BRCA2, but is not associated with a clinically relevant increase in breast cancer risk. Importantly, we have carried out a comprehensive analysis of the functional consequences of loss of exon 12 of BRCA2, using a murine ES 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14 cell system, wherein functional BRCA2 is required to rescue Brca2-null murine ES cells (Kuznetsov et al., 2008) .
Inappropriate splicing out of functionally critical exons is associated with disease. Most of the mutations that affect splicing are those that disrupt splice sites (Hastings and Krainer, 2001 ). More recently, however, exonic mutations that affect splicing have been identified . Our results show that BRCA2: c.6853A>G is one such variant, and that a degree of exclusion of exon 12 is seen in alleles without this variant (Figures 1 and   2 ). It appears that ESEs may be present in exon 12 of BRCA2 ( Figure 1A) , and it is notable that I2285, and the surrounding amino acids (KRRGEPS_I_KRNLLNEFDR) are well conserved through vertebrate evolution. Thus, the question of the significance of loss of exon 12 is an interesting one. As noted, loss of exon 12 results in a BRCA2 protein that is shorter than the wild-type form only by 32 amino acids, and this part of BRCA2 does not contain any known important functional motifs. Nevertheless, BRCA2∆E12 has been reported to be more commonly found in breast cancers than in normal tissues from the same individuals (Bieche and Lidereau, 1999) . In this study of breast cancer and matched normal tissue from 12 women, the proportion of BRCA2∆E12 transcripts was higher in the tumor in four pairs, and in no pairs was the BRCA2∆E12 higher in the normal tissue than in the tumor tissue. Similarly, in a study of 7 ovarian cancer cell lines, 5 were found to have a two-to five-fold increase in BRCA2∆E12 compared with mean values found in cultures of normal human ovarian surface epithelium. The same over-expression in tumor cell lines, rather than normal epithelium, was seen in one of four breast cancer cell lines and one of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 15 four prostate cancer cell lines. In the case of DU-145, the wild-type isoform of BRCA2 was barely detectable, whereas the truncated isoform, BRCA2∆E12, was strikingly overexpressed (Rauh-Adelmann et al., 2000) . Despite these findings, the functional analyses presented here indicate that BRCA2∆E12 can assume the biological role of full-length BRCA2. Very likely, the increased level of BRCA2∆E12 in cancer cells is an epiphenomenon rather than a causative mechanism.
We do not think BRCA2∆E12 represents a clinically important splice variant of BRCA2.
Nevertheless, it is important to investigate all potentially deleterious intra-exonic VUS using several approaches. Although the allelic association study we have carried out has not ruled out a small effect on risk, 14,199 Ashkenazi Jewish cases and an equal number of controls would be required to rule out an odds ratio of 1.25 (with the same 1-β and ά as above). Therefore, it remains possible that the splicing out of exon 12 does result in some subtle perturbations in risk for breast cancer, but at the current time, we cannot detect such an effect, if is exists at all.
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Human Mutation
C.5946T wild type allele-specific PCR was performed with cDNA from a DBV LCL and a wildtype LCL, both exon 12 inclusion (of 1085bp) and skipping (of 989bp) transcripts were detected.
The schema for the allele-specific PCR reactions is shown in the next two figures (top, c.5946delT allele; bottom c.6853A>G allele).
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